logo-loader
viewValiRx PLC

ValiRx Plc enjoying strong industry interest in its cancer treatments

George Morris, chief operations officer at ValiRx Plc (LON:VAL), updates Proactive's Andrew Scott on developments across the company's portfolio.

Morris says advanced conversations are continuing with possible partners as they look to press ahead with the development of their flagship VAL401 lung cancer candidate.

Quick facts: ValiRx PLC

Price: 0.0375 GBX

AIM:VAL
Market: AIM
Market Cap: £4.6 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ValiRx PLC making 'striking and important' progress on lead cancer compounds

Oliver de Giorgio-Miller, chairman of ValiRx Plc's (LON:VAL), tells Proactive Investors that their two lead cancer compounds are at stages in their development that they offer potential investors an investable proposition and an attractive offering to joint venture partners. They’ve been...

on 11/4/18

2 min read